Industry News
Biotechnology Industry News
Boehringer Ingelheim has opened…
Boehringer Ingelheim has opened another front in its attack on chronic kidney disease, offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.
Big Pharma-backed Aktis Oncology…
Big Pharma-backed Aktis Oncology has announced plans to go public in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year.
Having kicked off the year with a…
Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another clinical-stage drug.
Ipsen may be a recent entrant into…
Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time.
AstraZeneca has fronted $100…
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma.
Ipsen’s oral small molecule…
Ipsen’s oral small molecule failed to reduce the progression of a genetic disease that gradually turns tendons and ligaments into bone, prompting the pharma to stop the study early.
Venture capital firm Aditum Bio is…
Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based drugmaker.
Merck & Co. is turning down…
Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks.
Altimmune has shared an update on…
Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual receptor agonist to continued weight loss
Boehringer Ingelheim has turned…
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment.
Longtime Pfizer R&D…
Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance Replicate’s early-stage pipeline
After a long and strange year,…
After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining immunology asset. The company’s tyrosine kinase 2 inhibitor GLPG3667 met the primary endpoint in
After taking a stab at becoming a…
After taking a stab at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical asset and returning to its drug discovery roots.
Daiichi Sankyo and Merck &…
Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial.
Founded by a team of…
Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis Therapeutics is off to the races with a $165 million series A to support the development of a dual
Athira Pharma has joined an…
Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.
The Coalition for Epidemic…
The Coalition for Epidemic Preparedness Innovations—already engaged in a strategic partnership with Moderna—has agreed to plug up to $54.3 million into a pivotal phase 3 trial for mRNA-1018, Moderna’s mRNA-based H5 pandemic influenza vaccine candidate.
Eli Lilly has shown patients…
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s Wegovy.
GSK is embarking on a journey with…
GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.
Takeda’s closely watched and…
Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials as the Japanese pharma looks to file the drug in the U.S. next year.